Novo Nordisk suspended from UK lobby group
LONDON, March 16 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO) has been suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years over what the ABPI on Thursday described as "serious breaches" of its code of practice.
ABPI's statement linked to a website of a self-regulatory body run by the association that pointed to a complaint alleging that Novo Nordisk had sponsored courses on weight management on LinkedIn for health professionals, without making clear the company's involvement.
- Read more about Novo Nordisk suspended from UK lobby group
- Log in or register to post comments